Capella FPX 4055 Assessment 4

Capella FPX 4055 Assessment 4

Name

Capella University

NURS-FPX4055 Optimizing Population Health through Community Practice

Prof. Name

Date

Health Promotion Plan Presentation

Good morning and welcome. We appreciate your presence at today’s session focused on preventing Human Papillomavirus (HPV) infection among adolescents and young adults aged 11 to 26 in Schwenksville, Pennsylvania. This presentation aims to enhance awareness of HPV, its association with various cancers, and the critical role of timely vaccination. We will also explore effective strategies for discussing vaccination with healthcare professionals and family members. This session aligns with SMART goals and the objectives of Healthy People 2030.

Presentation Overview

During the session, participants will:

• Learn essential facts about HPV, its transmission, and its carcinogenic potential.
• Understand the safety and efficacy of the HPV vaccine.
• Be encouraged to schedule HPV vaccination within 30 days.
• Develop confidence in communicating about the HPV vaccine with providers and family.
• Engage in interactive learning activities and discussions.
• Complete a post-session quiz and survey to evaluate knowledge and confidence.

Key Facts About HPV and Its Oncogenic Potential

HPV is a prevalent virus transmitted primarily through sexual contact. Only 68.7% of adolescents in Pennsylvania are fully vaccinated, with even lower coverage (48.7%) in rural towns like Schwenksville (PA.gov, 2025). HPV is a leading cause of cervical, anal, oropharyngeal, and genital cancers. Persistent infections, especially from high-risk strains like HPV 16 and 18, may lead to abnormal cellular changes and eventual cancer (Huber et al., 2021). Many infections remain asymptomatic for years, emphasizing the need for early vaccination and regular screenings to combat HPV-related cancers.

Advantages of Early HPV Vaccination

Administering the HPV vaccine before exposure is highly effective. Vaccination is most beneficial between ages 11 and 12, offering long-term protection.

Effective Communication Strategies

Initiating conversations about HPV vaccination involves thoughtful communication.

• Share Reliable Facts: Use credible sources like the CDC and WHO to highlight vaccine safety and cancer prevention efficacy.
• Ask Thoughtful Questions: Inquire about long-term health benefits or concerns to encourage open dialogue (Kassymbekova et al., 2023).
• Debunk Myths: Address misconceptions calmly, such as the belief that the vaccine promotes early sexual activity, by focusing on cancer prevention.

SMART Goals for Session Outcomes

The following SMART goals were collaboratively developed to track session success:

Evaluation of SMART Goal Achievement

To improve future sessions, family-involved discussions during events, more role-play scenarios, and extended or follow-up meetings could enhance participant outcomes.

Evaluation of Alignment with Healthy People 2030

The session contributed meaningfully to Healthy People 2030 goals, particularly those emphasizing increased adolescent vaccination rates and reduced HPV infections (U.S. Department of Health and Human Services, n.d.). While knowledge and communication goals were met, the lower commitment to vaccination highlights the need for targeted family outreach and myth-debunking strategies. Future sessions may include:

Capella FPX 4055 Assessment 4

• More evidence-supported content on vaccine safety.
• Enhanced family engagement opportunities.
• Ongoing follow-ups to reinforce the benefits of timely vaccination (Xu et al., 2024).

Conclusion

In summary, HPV vaccination is a critical tool for cancer prevention among youth in Schwenksville, PA. The session reinforced the importance of early intervention, education, and confident communication. Guided by SMART goals and national health priorities, this initiative supports healthier futures through informed, proactive community engagement.

References

Cheng, L., Wang, Y., & Du, J. (2020). Human papillomavirus vaccines: An updated review. Vaccines, 8(3), 391. https://doi.org/10.3390/vaccines8030391

Hoes, J., Pasmans, H., Schurink-van ’t Klooster, T. M., van der Klis, F. R. M., Donken, R., Berkhof, J., & de Melker, H. E. (2021). Review of long-term immunogenicity following HPV vaccination: Gaps in current knowledge. Human Vaccines & Immunotherapeutics, 18(1). https://doi.org/10.1080/21645515.2021.1908059

Huber, J., Mueller, A., Sailer, M., & Regidor, P.-A. (2021). Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite. Women’s Health, 17, 174550652110207. https://doi.org/10.1177/17455065211020702

Kassymbekova, F., Zhetpisbayeva, I., Tcoy, E., Dyussenov, R., Davletov, K., Rommel, A., & Glushkova, N. (2023). Exploring HPV vaccine knowledge, attitudes, barriers and information sources among parents, health professionals and teachers in Kazakhstan: A mixed-methods study protocol. BMJ Open, 13(9), e074097. https://doi.org/10.1136/bmjopen-2023-074097

Capella FPX 4055 Assessment 4

PA.gov. (2025). Dear VFC provider. https://www.pa.gov/content/dam/copapwp-pagov/en/health/documents/topics/documents/programs/immunizations/3.3.25%…

U.S. Department of Health and Human Services. (n.d.). Healthy People 2030: Increase the proportion of adolescents who receive recommended doses of the HPV vaccine. https://health.gov/healthypeople